Clinical and biological characteristics of familial benign prostatic hyperplasia

Journal of Urology

Volumn 157, Issue 3, 1997, Pages 876-879

  Sanda, Martin G ^a   Doehring, Christopher B ^a   Binkowitz, Bruce ^a   Beaty, Terri H ^a   Partin, Alan W ^a   Hale, Erika ^a   Stoner, Elizabeth ^a   Walsh, Patrick C ^a  

^a NONE

Author keywords

androgens; genes; prostate; prostatic hypertrophy

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAMILIAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE FLOW RATE;

EID: 0031021661     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65069-9     Document Type: Article

References (20)

1. Huggins, C.: The etiology of benign prostatic hypertrophy. Bull. New York Acad. Med., 23: 696, 1947.
2. Coffey, D. S. and Walsh, P. C.: Clinical and experimental studies of benign prostatic hyperplasia. Urol. Clin. N. Amer., 17: 461, 1990.
3. Sanda, M. G., Beaty, T. H., Stutzman, R. E., Childs, B. and Walsh, P. C.: Genetic susceptibility of benign prostatic hyperplasia. J. Urol., 152: 115, 1994.
4. Roberts, R. O., Rhodes, T., Panser, L. A., Girman, C. J., Chute, C. G., Guess, H. A., Oesterling, J. E., Lieber, M. M. and Jacobsen, S. J.: Association between family history of benign prostatic hyperplasia and urinary symptoms: results of a population-based study. Amer. J. Epidemiol., 142: 965, 1995.
5. Partin, A. W., Page, W. F., Lee, B. R., Sanda, M. G., Miller, R. N. and Walsh, P. C.: Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology, 44: 646, 1994.
6. White, J. J., Nuewirth, H., Miller, C. D. and Schneider, E. L.: DNA alterations in prostatic adenocarcinoma and benign prostatic hyperplasia: detection by DNA fingerprint analyses. Mutat. Res., 237: 37, 1990.
7. Bedford, M. T. and van Helden, P. D.: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res., 47: 5274, 1987.
8. Partin, A. W., Getzenberg, R. H., CarMichael, M. J., Vindivich, D., Yoo, J., Epstein, J. I. and Coffey, D. S.: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res., 53: 744, 1993.
9. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B. and Ng, J. for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. New Engl. J. Med., 327: 1185, 1992.
10. Arrighi, H. M., Guess, H. A., Metter, E. J. and Fozard, J. L.: Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate, 16: 253, 1990.
11. Girman, C. J., Jacobsen, S. J., Guess, H. A., Oesterling, J. E., Chute, C. G., Panser, L. A. and Lieber, M. M.: Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J. Urol., 153: 1510, 1995.
12. Jensen, K. M. E., Bruskewitz, R. C., Iversen, P. and Madsen, P. O.: Significance of prostatic weight in prostatism. Urol. Int., 38: 173, 1983.
13. Barry, M. J., Cockett, A. T. K., Holtgrewe, H. L., McConnell, J. D., Sihelnik, S. A. and Winfield, H. N.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol., 150: 351, 1993.
14. Tan, H. K., Höfner, K., Kramer, A. E. J. L., Thon, W. F., Grunewald, V. and Jonas, U.: Benign prostatic hypertrophy: prostatic size, obstruction parameters, detrusor contractility and their interdependence. Neurourol. Urodyn., 12: 412, 1993.
15. Ruud Bosch, J. L. H., Kranse, R., van Mastrigt, R. and Schröder, F. H.: Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J. Urol., 153: 689, 1995.
16. Peters, C. A. and Walsh, P. C.: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New Engl. J. Med., 317: 599, 1987.
17. Isaacs, J. T. and Coffey, D. S.: Etiology and disease process of benign prostatic hyperplasia. Prostate, suppl., 2: 33, 1989.
18. Steiner, M. S.: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol., 153: 1085, 1995.
19. Tutrone, R. F., Jr., Ball, R. A., Ornitz, D. M., Leder, P. and Richie, J. P.: Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J. Urol., 149: 633, 1993.
20. Begun, F. P., Story, M. T., Hopp, K. A., Shapiro, E. and Lawson, R. K.: Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J. Urol., 153: 839, 1995.